Programme Overview

<table>
<thead>
<tr>
<th>ROOM: SILVER</th>
<th>RED</th>
<th>BLUE</th>
<th>YELLOW</th>
</tr>
</thead>
</table>

**Wednesday 20 March**

**Opening Ceremony, Arts & Humanities Award & Clinical Science Award**  
08:00-09:00

**Clinical Symposium**  
Immunotherapy beyond PD1/PDL1 checkpoint inhibitors and newer Antibody-drug-conjugates: the basics and the future  
09:00-10:30

**Coffee Break (free of charge) / Poster in the Spotlight in Exhibition Hall | 10:30-11:00**

**Young Investigator Innovation Award and Oral abstracts**  
11:00-12:55

**Europa Donna session**  
Can we reduce breast cancer risk?  
11:30-12:30

**Cashbar lunch in Exhibition Hall / Poster Area | 12:30-14:00**

**Plenary Session**  
Keynote  
14:00-14:30

**Debate**  
HER2 Low  
14:45-15:45

**Society Session**  
European Society of Surgical Oncology (ESSO): Controversies in breast cancer surgery  
14:45-15:45

**Society Session**  
European Society of Pathology (ESP): Biomarkers in breast cancers and biological perspectives  
14:45-15:45

**Coffee Break (free of charge) / Industry Forum in Exhibition Hall | 15:45-16:15**

**Clinical Symposium**  
Invasive lobular breast cancer (ILC)  
16:15-17:45

**Clinical Symposium**  
Towards second generation early detection of breast cancer  
16:15-17:45

**Welcome reception in Exhibition Hall | 17:45-19:00**

Programme subject to change. For the latest visit [www.eortc.org/ebcc](http://www.eortc.org/ebcc)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:30</td>
<td>Clinical Symposium&lt;br&gt;Treatment of HR+ HER2- ABC: current standard of care &amp; perspectives</td>
</tr>
<tr>
<td>09:00-10:00</td>
<td>Young Investigator Session&lt;br&gt;Clinical and Translational Breast Cancer Research: Navigating Challenges and Unlocking Potential for Young Investigators</td>
</tr>
<tr>
<td>09:30-10:55</td>
<td>Young Investigator Innovation Award and Oral abstracts</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>Europa Donna session&lt;br&gt;Equal access to innovation in breast cancer treatment</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>Society Session&lt;br&gt;European Society of Breast Imaging (EUSOBi): Towards Image guided modulation of breast cancer therapy.</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Coffee Break (free of charge) / Poster in the Spotlight in Exhibition Hall</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>Debate&lt;br&gt;This house believes that doing more surgery to get access to grea adjuvant therapies among whi CDK4/6 inhibitors is a backward step</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>Society Session&lt;br&gt;European Society of Breast Cancer Specialists (EUSOMA): The multidisciplinary meeting (MDM) in a Breast Centre: a real-life case discussion</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>Group Session&lt;br&gt;Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) - Progress Report</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>Society Session&lt;br&gt;European Association for Cancer Research (EACR) - Breast cancer progression: new approaches to answer long-standing questions</td>
</tr>
<tr>
<td>12:30-14:00</td>
<td>Cashbar lunch in Exhibition Hall / Poster Area</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>Debate&lt;br&gt;This house believes that pembrolizumab needs to be continued as post-neoadjuvant treatment in patients with TNBC disease</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>Multidisciplinary Team in the Real World&lt;br&gt;Management of individuals with breast cancer germinne susceptibility</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>Clinical Symposium&lt;br&gt;Can real world data replace the traditional control arm in a trial?</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>Clinical Symposium&lt;br&gt;Lifestyle interventions to improve quality of care after breast cancer</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>Society Session&lt;br&gt;European SocieTy for Radiotherapy &amp; Oncology (ESTRO): Early Breast Cancer Radiation Therapy Challenges in the Oncoplastic Era</td>
</tr>
<tr>
<td>16:45-17:15</td>
<td>Coffee Break (free of charge) / Industry Forum in Exhibition Hall</td>
</tr>
<tr>
<td>17:15-18:15</td>
<td>Multidisciplinary Team in the Real World&lt;br&gt;Management of the old frail patient</td>
</tr>
<tr>
<td>17:15-18:15</td>
<td>Best Practice&lt;br&gt;What survivorship means for breast cancer patients &amp; physicians</td>
</tr>
</tbody>
</table>
## Friday 22 March

### Clinical Symposium
- **De-escalation of axillary therapy after upfront surgery and after primary systemic therapy**
  - **08:00-09:30**

### Clinical Symposium
- **Brain metastases**
  - **08:00-09:30**

### Oral abstracts session
- **09:30-11:15**

### Europa Donna session
- I want to be able to work, if I can
  - **10:00-11:00**

### Coffee Break (free of charge) / Poster in the Spotlight in Exhibition Hall
- **11:00-11:30**

#### Debates
- **Debate**
  - Adjuvant CDK4/6-inhibitors
  - **11:30-12:30**

- **Debate**
  - This house believes that a second breast conserving surgery should always be performed in case of small recurrence early disease
  - **11:30-12:30**

#### Best practice
- Breast reconstruction and radiation therapy
  - **11:30-12:30**

### Cashbar lunch in Exhibition Hall / Poster Area
- **12:30-14:00**

### Manifesto Session
- **Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe**
  - **14:00-15:10**

### Closing Session
- **Keynote**
  - **15:10-15:40**